JP2023548342A5 - - Google Patents

Info

Publication number
JP2023548342A5
JP2023548342A5 JP2023526539A JP2023526539A JP2023548342A5 JP 2023548342 A5 JP2023548342 A5 JP 2023548342A5 JP 2023526539 A JP2023526539 A JP 2023526539A JP 2023526539 A JP2023526539 A JP 2023526539A JP 2023548342 A5 JP2023548342 A5 JP 2023548342A5
Authority
JP
Japan
Prior art keywords
degrees
optionally substituted
alkyl
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023526539A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023548342A (ja
JP7825618B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/058260 external-priority patent/WO2022099011A1/en
Publication of JP2023548342A publication Critical patent/JP2023548342A/ja
Publication of JP2023548342A5 publication Critical patent/JP2023548342A5/ja
Application granted granted Critical
Publication of JP7825618B2 publication Critical patent/JP7825618B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023526539A 2020-11-06 2021-11-05 二環式１，４－ジアゼパノン及びその治療的使用 Active JP7825618B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063110776P 2020-11-06 2020-11-06
US63/110,776 2020-11-06
PCT/US2021/058260 WO2022099011A1 (en) 2020-11-06 2021-11-05 Bicyclic 1,4-diazepanones and therapeutic uses thereof

Publications (3)

Publication Number Publication Date
JP2023548342A JP2023548342A (ja) 2023-11-16
JP2023548342A5 true JP2023548342A5 (enExample) 2024-11-12
JP7825618B2 JP7825618B2 (ja) 2026-03-06

Family

ID=78806729

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023526539A Active JP7825618B2 (ja) 2020-11-06 2021-11-05 二環式１，４－ジアゼパノン及びその治療的使用

Country Status (12)

Country Link
US (3) US11981644B2 (enExample)
EP (1) EP4240724A1 (enExample)
JP (1) JP7825618B2 (enExample)
KR (1) KR20230122002A (enExample)
CN (1) CN116635378A (enExample)
AR (1) AR124008A1 (enExample)
AU (1) AU2021373814A1 (enExample)
CL (1) CL2023001301A1 (enExample)
IL (1) IL302665A (enExample)
MX (1) MX2023004745A (enExample)
TW (1) TWI921403B (enExample)
WO (1) WO2022099011A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7825618B2 (ja) 2020-11-06 2026-03-06 サイトキネティックス， インコーポレイテッド 二環式１，４－ジアゼパノン及びその治療的使用
JP2025527504A (ja) * 2022-08-18 2025-08-22 サイトキネティックス， インコーポレイテッド 骨格筋速筋型ミオシン阻害剤としてのインダン誘導体及びクマラン誘導体
CN120202194A (zh) 2022-11-16 2025-06-24 巴斯夫欧洲公司 作为杀真菌剂的取代的四氢苯并二氮杂䓬
WO2024104818A1 (en) 2022-11-16 2024-05-23 Basf Se Substituted benzodiazepines as fungicides
EP4619392A1 (en) 2022-11-16 2025-09-24 Basf Se Substituted benzodiazepines as fungicides

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
KR100477070B1 (ko) 1994-03-25 2006-04-21 이소테크니카 인코포레이티드 중수소화작용에의한의약품의효능강화법
WO1995028399A1 (en) 1994-04-15 1995-10-26 Glaxo Wellcome Inc. A method of inducing cholecystokinin agonist activity using 1,4-benzodiazepine compounds
US6410254B1 (en) 1999-05-18 2002-06-25 Cytokinetics Compositions and assays utilizing ADP or phosphate for detecting protein modulators
US7202051B1 (en) 1999-05-18 2007-04-10 Cytokinetics, Inc. Compositions and assays utilizing ADP or phosphate for detecting protein modulators
US6743599B1 (en) 1999-05-18 2004-06-01 Cytokinetics, Inc. Compositions and assays utilizing ADP or phosphate for detecting protein modulators
US6908921B2 (en) 2002-12-13 2005-06-21 Merck & Co., Inc. Quinoxalinone derivatives as bradykinin B1 antagonists
US20060217370A1 (en) * 2005-02-18 2006-09-28 Ethan Burstein Compounds useful for the treatment and prevention of pain and screening methods therefor
CA2620414A1 (en) 2005-08-26 2007-03-01 Methylgene Inc. Benzodiazepine and benzopiperazine analog inhibitors of histone deacetylase
BRPI0714725B1 (pt) * 2006-08-02 2021-05-25 Cytokinetics, Inc Entidade química, composição farmaceuticamente aceitável, e, uso de uma entidade química
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
CN101522681B (zh) * 2006-08-02 2012-10-03 赛特凯恩蒂克公司 特定的化学个体、组合物和方法
WO2008144483A2 (en) 2007-05-18 2008-11-27 Armgo Pharma, Inc. Agents for treating disorders involving modulation of ryanodine receptors
JP5640208B2 (ja) * 2008-01-24 2014-12-17 パナセア バイオテック リミテッド 新規複素環化合物
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
EP2560488B1 (en) 2010-04-23 2015-10-28 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
WO2013151938A1 (en) 2012-04-02 2013-10-10 Cytokinetics, Inc. Methods for improving diaphragm function
BR112014025251B1 (pt) 2012-04-11 2021-03-02 Fady Malik uso de um ativador de troponina de músculo esquelético e composição compreendendo o mesmo
EP2708535A1 (en) * 2012-05-11 2014-03-19 Les Laboratoires Servier Agents for treating disorders involving modulation of ryanodine receptors
US9566310B2 (en) 2012-09-10 2017-02-14 Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Reno Methods of treating muscular dystrophy
LT3137622T (lt) 2014-04-29 2022-04-25 Cytokinetics, Inc. Gyvybinio pajėgumo nykimo mažinimo būdai
US9987279B2 (en) 2014-09-09 2018-06-05 Astellas Pharma Inc. Pharmaceutical composition for prevention and/or treatment of urinary incontinence
SG11201806416XA (en) * 2016-02-12 2018-08-30 Astellas Pharma Inc Tetrahydroisoquinoline derivatives
CN114144410A (zh) 2019-07-19 2022-03-04 阿纳格纳斯生物技术股份有限公司 多芳基脲衍生物及其在治疗肌肉疾病中的用途
JP7825618B2 (ja) 2020-11-06 2026-03-06 サイトキネティックス， インコーポレイテッド 二環式１，４－ジアゼパノン及びその治療的使用
EP4518968A1 (en) 2022-05-04 2025-03-12 Cytokinetics, Inc. Bicyclic piperazinones and therapeutic uses thereof

Similar Documents

Publication Publication Date Title
ES2673160T5 (es) Moduladores selectivos del receptor de la esfingosina 1 fosfato y métodos de síntesis quiral
US9309224B2 (en) N-acyl-N′-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities
JP2024543983A5 (enExample)
US12012381B2 (en) Dimethyltryptamine analogues as nitric oxide delivery drugs
JP2011527334A5 (enExample)
EP2210890A1 (en) Oxadiazole derivatives as S1P1 receptor agonists
JP2006501295A5 (enExample)
JPWO2002062775A1 (ja) ２−アシルアミノチアゾール誘導体又はその塩
HU229935B1 (en) Dual action antibiotics
JP2007527919A5 (enExample)
JP7159440B2 (ja) ジカチオン化合物及びその製造方法と使用
JPWO2023195529A5 (enExample)
JP2007505931A5 (enExample)
JP2008502614A5 (enExample)
JP2013542267A5 (enExample)
JP5781093B2 (ja) 新たな置換イソキノリン誘導体
EP2997019A1 (en) Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
JP2007532627A5 (enExample)
JP2024510939A5 (enExample)
RU2006138426A (ru) Производные тиазолопиридина, содержащие их фармацевтические композиции и способы лечения состояний, опосредованных глюкокиназой
HUP0400238A2 (hu) Pirrolidin-oxadiazol- és tiadiazolszármazékok, előállításuk és ezeket tartalmazó gyógyszerkészítmények
JP2023541040A5 (enExample)
HUT58063A (en) Process for producing 5 ht under 3 antagonist heterocyclic guanidine derivatives
JP2022554330A5 (enExample)
JP2024546600A5 (enExample)